S-1/A: Longeveron Inc. Announces Public Offering of Class A Common Stock and Warrants

Longeveron Inc. is offering up to 2,461,538 shares of Class A Common Stock along with warrants in a public offering to fund clinical trials and general corporate purposes.

Summary

• Longeveron Inc. is offering up to 2,461,538 shares of Class A common stock, along with Class A common warrants to purchase the same number of shares.
• Each share or pre-funded warrant is sold with a Class A common warrant.
• The assumed combined public offering price is $3.25 per share and warrant, based on the closing price on March 28, 2024.
• Class A common warrants have an exercise price to be determined, are exercisable upon issuance, and expire five years from the issue date.
• Pre-funded warrants are offered as an alternative to shares for purchasers exceeding beneficial ownership limits (4.99% or 9.99%).
• The purchase price for each pre-funded warrant and accompanying Class A common warrant will equal the price per share of Class A common stock and accompanying Class A common warrant being sold to the public in this offering, minus $0.001, and the exercise price of each pre -funded warrant will be $0.001 per share.
• The offering terminates on May 15, 2024, unless terminated earlier.
• H.C. Wainwright & Co., LLC is acting as the exclusive placement agent.
• The company will pay the placement agent a cash fee equal to 7.0% of the gross proceeds raised in this offering.
• The company will also reimburse the placement agent for certain expenses, including a management fee equal to 1.0% of the aggregate gross proceeds raised in this offering, reimbursement for non -accountable expenses in an amount up to $35,000, and legal fees and other out -of-pocket expenses in the amount of up to $100,000.
• Placement agent warrants to purchase 7.0% of the shares sold in the offering will also be issued.
• The company intends to use the net proceeds for clinical and regulatory development of Lomecel-B, obtaining regulatory approvals, capital expenditures, working capital, and other general corporate purposes.
• The company effected a 1-for-10 reverse stock split on March 26, 2024.
• The company received a notice from Nasdaq on March 4, 2024, that its Class A common stock did not meet the $1.00 minimum bid price required for continued listing on the Nasdaq Capital Market.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the company's financial situation, Nasdaq compliance issues, and the dilutive nature of the offering. However, the potential for Lomecel-B and the capital raise to support its development provide some positive aspects.

Positives

• The offering aims to raise capital for the clinical development of Lomecel-B, a promising regenerative medicine.
• The company has broad discretion in the application of the net proceeds.
• The company has engaged H.C. Wainwright & Co., LLC to act as its exclusive placement agent in connection with this offering.

Negatives

• The company has a history of losses and may not be able to achieve profitability going forward.
• The company may not be able to raise additional capital necessary to continue as a going concern.
• The company received a notice from Nasdaq on March 4, 2024, that its Class A common stock did not meet the $1.00 minimum bid price required for continued listing on the Nasdaq Capital Market.
• The company has broad discretion in how it uses the net proceeds of this offering, and it may not use these proceeds effectively or in ways with which you agree.
• The company may sell fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received by us, and investors in this offering will not receive a refund in the event that we do not sell an amount of securities sufficient to support our business goals and continued operations, including our near -term continued operations.

Risks

• The company's cash position and need to raise additional capital, the difficulties it may face in obtaining access to capital, and the dilutive impact it may have on investors.
• The company's financial performance, ability to continue as a going concern and ability to regain compliance and remain listed on the Nasdaq Capital Market.
• The ability of the company's clinical trials to demonstrate safety and efficacy of its product candidates, and other positive results.
• The timing and focus of the company's ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials.
• The size of the market opportunity for the company's product candidates, including estimates of the number of patients who suffer from the diseases the company is targeting.
• The success of competing therapies that are or may become available.
• The beneficial characteristics, safety, efficacy and therapeutic effects of the company's product candidates.
• The company's ability to obtain and maintain regulatory approval of its product candidates in the U.S., Japan, The Bahamas, and other jurisdictions.
• The company's plans relating to the further development of its product candidates, including additional disease states or indications it may pursue.
• The company's plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and its ability to avoid infringing the intellectual property rights of others.
• The need to hire additional personnel and the company's ability to attract and retain such personnel.
• The company's estimates regarding expenses, future revenue, capital requirements and needs for additional financing.

Future Outlook

The company intends to use the net proceeds for clinical and regulatory development of Lomecel-B, obtaining regulatory approvals, capital expenditures, working capital, and other general corporate purposes.

Industry Context

The announcement reflects a common strategy for clinical-stage biotechnology companies to raise capital to fund ongoing research and development activities. The offering structure, including the use of warrants, is a typical approach to attract investors.

Comparison to Industry Standards

• Comparable companies in the biotechnology sector, such as Mesoblast, Athersys, and Lineage Cell Therapeutics, have also utilized public offerings and warrant issuances to raise capital.
• The terms of the offering, including the placement agent fees and warrant coverage, are generally in line with industry standards for similar-sized companies.
• The focus on regenerative medicine and cell therapy aligns with broader industry trends in developing innovative treatments for unmet medical needs.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares and warrants.
• The capital raise could benefit employees by providing funding for continued operations and development.
• Customers (patients) could benefit from the development of Lomecel-B if it proves to be an effective treatment.
• Suppliers and creditors may benefit from the company's improved financial stability due to the capital raise.

Next Steps

• The company will proceed with the public offering, aiming to close by May 15, 2024.
• The company will work to meet Nasdaq's minimum bid price requirement.
• The company will use the proceeds to advance the clinical development of Lomecel-B and for general corporate purposes.

Key Dates

Keywords

Longeveron, Class A Common Stock, Warrants, Public Offering, Lomecel-B, Clinical Trials, Pre-funded Warrants, H.C. Wainwright, Placement Agent, Reverse Stock Split